40L cylinder laughing gas, Medical grade nitrous oxide

Nitrous Oxide Gas Suppliers

Medical  N2O Gas
40L cylinder 99.9%-99.999% industrial laughing gas ,medical grade nitrous oxide
Food grade N2O is produced by Ammonium Nitrate.
Widely used for hospital applications. Another common application is Nitro booster in high speed racing cars.
Common purity : 99.9%
Electronic purity : 99.999%
DSW Nitrous Oxide have been exported to many countries like India, Pakistan, Malaysia, Indonesia, Australia, Netherlands, and Mexico.

Medical grade nitrous oxide has the ability to lower down the mental consciousness of patients. This helps them tolerate pain and longer surgical processes.

Product packaging
size 10L 40L
Outside Diameter 140/152/159 mm 219mm
Height 950/890/790mm 1333mm
Weight 13.4/12.6/12.7 KGS 48 KGS
Working pressure 150BAR 150BAR
Test pressure 250BAR 250BAR
Material 37Mn 37Mn
Wall thickness 4.1/4.4/4.4 mm 5.7MM
Standard ISO9809-3 ISO9809-3
Filling weight( N2O) 5 KGS 20/24 KGS

medical grade laughing gas

medical grade nitrous oxide

medical grade nitrous oxide
Nitrous oxide is a clear, colourless, slightly sweet smelling, non-irritating gas supplied in blue (ultramarine) cylinders as determined by AS4484.
Cylinder sizes available in 1.5L, 3.0L, 10L, 25L, 35L, 50L as measured by nominal water capacity.

Purity 99.9% NO Nitric Oxide Gas Medical Grade With Colorless Appearance
CAS No.: 10102-43-9
EINECS No.: 233-271-0
UN No.: UN1660
Purity: 99.9%
Dot Class: 2.3
Appearance: Colorless
Grade Standard: Medical Grade

Nitric oxide dosing information
Usual Pediatric Dose for Respiratory Failure:

Recommended dose: 20 ppm
Duration of therapy: 14 days or until the underlying oxygen desaturation has resolved
Weaning off: Down-titrate in several steps, pausing several hours at each step to monitor for hypoxemia

Comments:
-Doses above 20 ppm are not recommended
-Avoid abrupt discontinuation
Use(s): To improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near term (over 34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents